Claerhout I, Goegebuer A, Van Den Broecke C, Kestelyn Ph
Department of Ophthalmology (0P1), Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium.
Graefes Arch Clin Exp Ophthalmol. 2004 Aug;242(8):648-53. doi: 10.1007/s00417-003-0805-7.
To evaluate the outcome of Acanthamoeba keratitis with respect to the delay in diagnosis.
A retrospective review of the records of 14 patients treated for Acanthamoeba keratitis was carried out. Delay in diagnosis was correlated with risk factors, clinical presentation, method of diagnosis, final visual acuity and need for penetrating keratoplasty.
Based on the time interval between the first symptoms and the diagnosis of Acanthamoeba keratitis, it appeared that patients could be divided into two groups: an early treatment group (group I), consisting of six patients treated within 18 days of onset of symptoms, and a late treatment group (group II), composed of eight patients treated beyond that time. There were no statistically significant differences between the two groups as far as risk factors, clinical presentation, accuracy of diagnosis and method of diagnosis were concerned, although more extensive and deeper corneal involvement was noted in group II. Improvement in visual acuity following medical therapy was seen in all six patients in the early group and in three (37%) of the eight patients in the late group. One patient in group I needed urgent penetrating keratoplasty for corneal necrosis. In group II, two patients underwent penetrating keratoplasty à chaud to prevent corneal perforation and three patients needed penetrating keratoplasty to restore functional visual acuity.
A diagnostic delay of less than 18 days between onset of symptoms and start of anti-amoebic treatment results in a better final VA after medical treatment and obviates the need for urgent and elective penetrating keratoplasty.
评估棘阿米巴角膜炎在诊断延迟方面的转归情况。
对14例棘阿米巴角膜炎患者的治疗记录进行回顾性分析。将诊断延迟与危险因素、临床表现、诊断方法、最终视力以及穿透性角膜移植术的需求进行关联分析。
根据首次症状出现至棘阿米巴角膜炎确诊之间的时间间隔,患者似乎可分为两组:早期治疗组(I组),由6例在症状出现后18天内接受治疗的患者组成;晚期治疗组(II组),由8例在该时间之后接受治疗的患者组成。就危险因素、临床表现、诊断准确性和诊断方法而言,两组之间无统计学显著差异,尽管II组角膜受累范围更广、程度更深。早期组的所有6例患者经药物治疗后视力均有改善,晚期组的8例患者中有3例(37%)视力改善。I组中有1例患者因角膜坏死需要紧急进行穿透性角膜移植术。在II组中,有2例患者接受了紧急穿透性角膜移植术以预防角膜穿孔,3例患者需要进行穿透性角膜移植术以恢复功能性视力。
症状出现与开始抗阿米巴治疗之间的诊断延迟少于18天,经药物治疗后最终视力较好,且无需进行紧急和选择性穿透性角膜移植术。